A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Background: A detailed understanding of the pathological processes involved in genetic frontotemporal dementia is critical in order to provide the patients with an optimal future treatment. Protein levels in CSF have the potential to reflect different pathophysiological processes in the brain. We aimed to identify and evaluate panels of CSF proteins with potential to separate symptomatic individuals from individuals without clinical symptoms (unaffected), as well as presymptomatic individuals from mutation non-carriers. Methods: A multiplexed antibody-based suspension bead array was used to analyse levels of 111 proteins in CSF samples from 221 individuals from families with genetic frontotemporal dementia. The data was explored using LASSO and Random forest. Results: When comparing affected individuals with unaffected individuals, 14 proteins were identified as potentially important for the separation. Among these, four were identified as most important, namely neurofilament medium polypeptide (NEFM), neuronal pentraxin 2 (NPTX2), neurosecretory protein VGF (VGF) and aquaporin 4 (AQP4). The combined profile of these four proteins successfully separated the two groups, with higher levels of NEFM and AQP4 and lower levels of NPTX2 in affected compared to unaffected individuals. VGF contributed to the models, but the levels were not significantly lower in affected individuals. Next, when comparing presymptomatic GRN and C9orf72 mutation carriers in proximity to symptom onset with mutation non-carriers, six proteins were identified with a potential to contribute to a separation, including progranulin (GRN). Conclusion: In conclusion, we have identified several proteins with the combined potential to separate affected individuals from unaffected individuals, as well as proteins with potential to contribute to the separation between presymptomatic individuals and mutation non-carriers. Further studies are needed to continue the investigation of these proteins and their potential association to the pathophysiological mechanisms in genetic FTD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988 · cited 1×
“Elevated CSF levels of NEFL is a marker of neuroaxonal damage [5] and has been investigated in a wide range of neurological conditions [6, 7].”
BackgroundSelf-citationPhysiological Roles of Aquaporin-4 in Brain
Nagelhus, E. A., & Ottersen, O. P. (2013) · Physiological Reviews · doi:10.1152/physrev.00011.2013 · Cited by 766 · cited 1×
“close to blood vessels (perivascular) with a particularly high expression at the blood brain barrier and blood CSF barrier [53].”
BackgroundBridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the NFL Group, Alvarez-Cermeño, J. C., Andreasson, U., Axelsson, M., Bäckström, D. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1534 · Cited by 764
Self-citationRohrer, J. D., Nicholas, J. M., Cash, D. M., van Swieten, J., Dopper, E., Jiskoot, L., van Minkelen, R., Rombouts, S. A., Cardoso, M. J., Clegg, S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70324-2 · Cited by 538
Self-citationAn update on genetic frontotemporal dementia
Greaves, C. V., & Rohrer, J. D. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09363-4 · Cited by 500
Self-citationNarp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing interneurons
Chang, M. C., Park, J. M., Pelkey, K. A., Grabenstatter, H. L., Xu, D., Linden, D. J., Sutula, T. P., McBain, C. J., & Worley, P. F. (2010) · Nature Neuroscience · doi:10.1038/nn.2621 · Cited by 316
Moore, K. M., Nicholas, J., Grossman, M., McMillan, C. T., Irwin, D. J., Massimo, L., Van Deerlin, V. M., Warren, J. D., Fox, N. C., Rossor, M. N., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30394-1 · Cited by 313 · cited 2×
“There was no statistically significant difference in age between PMC and NC. Years to expected onset was calculated based on the mean age at disease onset in the respective genetic groups (C9orf72, GRN, MAPT) according to Moore et al. 2020 [18].”
MethodSelf-citationDuits, F. H., Brinkmalm, G., Teunissen, C. E., Brinkmalm, A., Scheltens, P., Van der Flier, W. M., Zetterberg, H., & Blennow, K. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0335-x · Cited by 137
Cited by
del Campo, M., Zetterberg, H., Gandy, S., Onyike, C. U., Oliveira, F., Udeh‐Momoh, C., Lleó, A., Teunissen, C. E., & Pijnenburg, Y. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12643 · Cited by 52
Synaptic Loss in Frontotemporal Dementia Revealed by [ 11 C ] UCB‐J Positron Emission Tomography
Malpetti, M., Jones, P. S., Cope, T. E., Holland, N., Naessens, M., Rouse, M. A., Rittman, T., Savulich, G., Whiteside, D. J., Street, D., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26543 · Cited by 53
Self-citationMulti-omics analysis reveals the key factors involved in the severity of the Alzheimer’s disease
Meng, L., Jin, H., Yulug, B., Altay, O., Li, X., Hanoglu, L., Cankaya, S., Coskun, E., Idil, E., Nogaylar, R., et al. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01578-6 · Cited by 49
Sogorb-Esteve, A., Nilsson, J., Swift, I. J., Heller, C., Bocchetta, M., Russell, L. L., Peakman, G., Convery, R. S., van Swieten, J. C., Seelaar, H., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01042-3 · Cited by 39
Self-citation
Metadata
- Authors
- Bergström, S., Öijerstedt, L., Remnestål, J., Olofsson, J., Ullgren, A., Seelaar, H., van Swieten, J. C., Synofzik, M., Sanchez-Valle, R., Moreno, F., Finger, E., Masellis, M., Tartaglia, C., Vandenberghe, R., Laforce, R., Galimberti, D., Borroni, B., Butler, C. R., Gerhard, A., Ducharme, S., Rohrer, J. D., Månberg, A., Graff, C., Nilsson, P., (GENFI), O. B. O. T. G. F. D. I., Jiskoot, L., Rowe, J. B., de Mendonça, A., Tagliavini, F., Santana, I., Le Ber, I., Levin, J., Danek, A., Otto, M., Frisoni, G., Ghidoni, R., Sorbi, S., Pasquier, F., Jelic, V., Andersson, C., Afonso, S., Almeida, M. R., Anderl-Straub, S., Antonell, A., Archetti, S., Arighi, A., Balasa, M., Barandiaran, M., Bargalló, N., Bartha, R., Bender, B., Benussi, A., Benussi, L., Bessi, V., Binetti, G., Black, S., Bocchetta, M., Borrego-Ecija, S., Bras, J., Bruffaerts, R., Cañada, M., Cantoni, V., Caroppo, P., Cash, D., Castelo-Branco, M., Convery, R., Cope, T., Di Fede, G., Díez, A., Duro, D., Fenoglio, C., Ferrari, C., Ferreira, C. B., Fox, N., Freedman, M., Fumagalli, G., Gabilondo, A., Gasparotti, R., Gauthier, S., Gazzina, S., Giaccone, G., Gorostidi, A., Greaves, C., Guerreiro, R., Heller, C., Hoegen, T., Indakoetxea, B., Jiskoot, L., Karnath, H.-O., Keren, R., Langheinrich, T., Leitão, M. J., Lladó, A., Lombardi, G., Loosli, S., Maruta, C., Mead, S., Meeter, L., Miltenberger, G., van Minkelen, R., Mitchell, S., Moore, K., Nacmias, B., Nicholas, J., Olives, J., Ourselin, S., Padovani, A., Panman, J., Papma, J. M., Peakman, G., Pievani, M., Pijnenburg, Y., Polito, C., Premi, E., Prioni, S., Prix, C., Rademakers, R., Redaelli, V., Rittman, T., Rogaeva, E., Rosa-Neto, P., Rossi, G., Rosser, M., Santiago, B., Scarpini, E., Schönecker, S., Semler, E., Shafei, R., Shoesmith, C., Tábuas-Pereira, M., Tainta, M., Taipa, R., Tang-Wai, D., Thomas, D. L., Thompson, P., Thonberg, H., Timberlake, C., Tiraboschi, P., Todd, E., Van Damme, P., Vandenbulcke, M., Veldsman, M., Verdelho, A., Villanua, J., Warren, J., Wilke, C., Woollacott, I., Wlasich, E., Zetterberg, H., & Zulaica, M.
- Venue
- Molecular Neurodegeneration
- Published
- 2021-11-27
- Volume
- 16
- Issue
- 1
- Pages
- 79-79
- ISSN
- 1750-1326 (ISSN-L)
- OpenAlex
- W3215312374
- Cited by
- 36
- References
- 23
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. https://app.cochat.ai/papers/10.1186/s13024-021-00499-4
- The paper
- Bergström, S., Öijerstedt, L., Remnestål, J., Olofsson, J., Ullgren, A., Seelaar, H., van Swieten, J. C., Synofzik, M., Sanchez-Valle, R., Moreno, F., Finger, E., Masellis, M., Tartaglia, C., Vandenberghe, R., Laforce, R., Galimberti, D., Borroni, B., Butler, C. R., Gerhard, A., . . . Zulaica, M. (2021). A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-021-00499-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.